Clinical Trial Update: Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome [Phase 4]

View source ↗

Summary

Phase 4 trial comparing fixed-dose versus phenotype-based prasugrel dosing in Asians with acute coronary syndrome to match therapeutic window.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• PRASUGREL (prasugrel)

Snippet

Sponsor: Gyeongsang National University Hospital | Conditions: Acute Coronary Syndrome, Platelet Thrombus | Phase 4 | Status: COMPLETED